PharmaTelevision - How SkyePharma Makes Good Drugs Better

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How SkyePharma Makes Good Drugs Better

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

One important role of drug delivery companies is to improve or reposition existing drugs by the application of their own technologies. Christopher de Souza, VP Business Development, explains the technologies that SkyePharma is developing and how they will fit into current clinical needs. He discusses the changes that the company and drug delivery industry have gone through recently with a focus on inhalation products and the extent to which they will be used in the future.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

SkyePharma's technology platform from a drug delivery perspective

Fintan Walton:

Hello and welcome to Pharmaventures business review here in Mannheim, Germany. On this show I have Christopher de Souza who is Vice President of Business Development at SkyePharma and you're based in Cambridge, Massachusetts. Welcome to the show.

Christopher de Souza:

Thank you.

Fintan Walton:

Christopher, SkyePharma is a company that has been around for several years now over since the early 1990's. It's a company that has clearly made it's mark in the area of drug delivery. I know that in it's journey it's acquired a number of companies and products in that journey, it also at one stage considered itself more as a specialty pharmaceutical company but today it still is a drug delivery company?

Christopher de Souza:

That's right, that's right.

Fintan Walton:

Yeah, so remind us then of what SkyePharma is in terms of it's technologies? What is your technology platform from a drug delivery perspective?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Christopher de Souza

VP Business Development

Dr.Christopher de Souzanot only holds the position of VP Business Development at SkyePharma, but is also a Consultant at MOITI, the Massachusetts Office of International Trade & Investment and a Co-Chair of Business Development Committee at the Massachusetts Biotech Council. Before joining SkyePharma, Christopher de Souza was both a Consultant at Biopharmaceutical Business Development and a Director, Strategic Alliances at Novartis. Dr. de Souzastudied at Rutgers, The State University of New Jersey, the Louisiana State University and the Agricultural and Mechanical College at the University of Mumbai.

SkyePharma

SkyePharmais a specialist drug delivery company developing oral and inhalation products. They partner with a wide variety of companies from big pharmaceuticals, such as GlaxoSmithKline, Novartis, sanofi-aventis, AstraZeneca, Roche and Abbott Laboratories to a range of smaller specialty pharmaceutical companies. Whilst continuing to benefit from existing approved products, the Group aims to enhance it's product pipeline by identifying additional candidate products through it's own research as well as collaborations with partner companies. SkyePharma'sGeoclock and Geoclock technologies enable controlled- or timed-release versions of immediate-release products to be developed providing advantages to both partner companies and patients.